Literature DB >> 8611359

Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients.

S Furth1, A Neu, P Colombani, L Plotnick, M E Turner, B Fivush.   

Abstract

Three cases of insulin-requiring diabetes mellitus associated with tacrolimus (FK506) therapy in pediatric renal transplant patients are presented. New-onset diabetes mellitus has been reported with tacrolimus therapy post liver and kidney transplants in up to 12% of adult patients, but is thought to be rare in pediatrics. Although insulin requirement with tacrolimus therapy has been occasionally reported in adolescent patients post liver transplant, only a single case in a pediatric kidney transplant recipient has been previously documented. These cases illustrate the significant diabetogenic effect of tacrolimus in pediatric renal transplant patients. As the use of tacrolimus becomes more prevalent in pediatric kidney transplantation, pediatric nephrologists should be aware of this potential complication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611359     DOI: 10.1007/bf00863448

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  12 in total

1.  New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients.

Authors:  V Scantlebury; R Shapiro; J Fung; A Tzakis; J McCauley; M Jordan; C Jensen; T Hakala; R Simmons; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 2.  Adverse effects associated with the use of FK 506.

Authors:  J J Fung; M Alessiani; K Abu-Elmagd; S Todo; R Shapiro; A Tzakis; D Van Thiel; J Armitage; A Jain; J McCauley
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication.

Authors:  P B Carroll; H Rilo; J Reyes; R Alejandro; Y Zeng; C Ricordi; A Tzakis; R Shapiro; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

4.  Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients.

Authors:  R M Jindal; I Popescu; M E Schwartz; S Emre; P Boccagni; C M Miller
Journal:  Transplantation       Date:  1994-08-15       Impact factor: 4.939

5.  Two-year experience with FK 506 in pediatric patients.

Authors:  A G Tzakis; J Reyes; S Todo; B Nour; R Shapiro; M Jordan; J McCauley; J Armitage; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

Review 6.  Posttransplant diabetes mellitus--a review.

Authors:  R M Jindal
Journal:  Transplantation       Date:  1994-12-27       Impact factor: 4.939

7.  Kidney transplantation under FK 506.

Authors:  T E Starzl; J Fung; M Jordan; R Shapiro; A Tzakis; J McCauley; J Johnston; Y Iwaki; A Jain; M Alessiani
Journal:  JAMA       Date:  1990-07-04       Impact factor: 56.272

8.  Posttransplant diabetes in kidney transplant recipients.

Authors:  E A Friedman; T P Shyh; M M Beyer; T Manis; K M Butt
Journal:  Am J Nephrol       Date:  1985       Impact factor: 3.754

9.  Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation.

Authors:  D Ellis; R Shapiro; M L Jordan; V P Scantlebury; N Gilboa; L Hopp; N Weichler; A G Tzakis; R L Simmons
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

10.  A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation.

Authors: 
Journal:  N Engl J Med       Date:  1994-10-27       Impact factor: 91.245

View more
  4 in total

1.  Tacrolimus induced diabetic ketoacidosis in nephrotic syndrome.

Authors:  Sumantra Sarkar; Rakesh Mondal; Madhumita Nandi; Anjan Kumar Das
Journal:  Indian J Pediatr       Date:  2012-06-02       Impact factor: 1.967

2.  Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients.

Authors:  Thomas E Burroughs; Jason P Swindle; Paolo R Salvalaggio; Krista L Lentine; Steven K Takemoto; Suphamai Bunnapradist; Daniel C Brennan; Mark A Schnitzler
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

3.  FK506 prevented bone loss in streptozotocin-induced diabetic rats via enhancing osteogenesis and inhibiting adipogenesis.

Authors:  Li-Hua Ni; Ri-Ning Tang; Cheng Yuan; Kai-Yun Song; Li-Ting Wang; Xiao-Chen Wang; Yu-Xia Zhang; Xiao-Liang Zhang; Dong-Dong Zhu; Bi-Cheng Liu
Journal:  Ann Transl Med       Date:  2019-06

4.  Characterization of Remitting and Relapsing Hyperglycemia in Post-Renal-Transplant Recipients.

Authors:  Alireza Boloori; Soroush Saghafian; Harini A Chakkera; Curtiss B Cook
Journal:  PLoS One       Date:  2015-11-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.